Skip to content
10-K

Annual Report

Terns Pharmaceuticals, Inc.

0000950170-25-042695

← back to feed
Filed
Mar 20, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 14, 2025 87.3M sh
Shares Diluted FY 2024 · Dec 31, 2023 71.26M sh
Capex FY 2024 · Dec 31, 2023 $52K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$67.39M
Cash And Equivalents FY 2024 · Dec 31, 2023 $79.93M
Current Liabilities FY 2024 · Dec 31, 2023 $11.94M
Total Liabilities FY 2024 · Dec 31, 2023 $13.15M
Current Assets FY 2024 · Dec 31, 2023 $267.43M
Total Assets FY 2024 · Dec 31, 2023 $268.52M
Eps Diluted FY 2024 · Dec 31, 2023 −$1.27
Eps Basic FY 2024 · Dec 31, 2023 −$1.27
Sga Expense FY 2024 · Dec 31, 2023 $39.06M
Net Income FY 2024 · Dec 31, 2023 −$90.21M
Operating Income FY 2024 · Dec 31, 2023 −$102.56M
Stockholders Equity FY 2024 · Dec 31, 2022 $276.94M